Company intelligence / Profile preview

Transfer

Heidelberg, Germany

Ownership: Private
Development stage: Other

Overview

Transfer Therapeutics is a biotechnology company focused on developing a novel class of RNA-based therapies that target transfer RNA (tRNA) biology. The company leverages its proprietary platform to modulate tRNA modifications and levels, which are often dysregulated in various cancers and genetic disorders. By targeting the translational machinery of the cell, Transfer Therapeutics aims to develop precision medicines that can overcome resistance mechanisms in oncology and address unmet needs in rare diseases. The company's approach represents a frontier in epitranscriptomics, focusing on the functional impact of tRNA on protein synthesis.

Therapeutic areas: OncologyRare Diseases
Modalities: RNA therapySmall moleculeOligonucleotide
Industry: Biotech

Beyond the preview

Go deeper on Transfer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transfer.

Explore the full profile